| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5731296 | ASTELLAS | Selective vasodilation by continuous adenosine infusion |
Mar, 2015
(9 years ago) | |
Adenoscan is owned by Astellas.
Adenoscan contains Adenosine.
Adenoscan has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Adenoscan are:
- US5731296
Adenoscan was authorised for market use on 18 May, 1995.
Adenoscan is available in solution;intravenous dosage forms.
Adenoscan can be used as selective vasodilation by continuous adenosine infusion.
The generics of Adenoscan are possible to be released after 24 March, 2015.
Drugs and Companies using ADENOSINE ingredient
Market Authorisation Date: 18 May, 1995
Treatment: Selective vasodilation by continuous adenosine infusion
Dosage: SOLUTION;INTRAVENOUS
How can I launch a generic of ADENOSCAN before it's drug patent expiration?
More Information on Dosage
ADENOSCAN family patents
